Investment Column: Cobham is more than just defensive

Immunodiagnostic Systs; Eckoh


Our view: Buy

Share price: 274.6p (-0.7p)

At first glance, two concerns spring to mind when looking at Cobham, the defence and aerospace electronics group. First, the world economy seems to be recovering from the financial crisis and traders are increasingly on the prowl for companies that track the rhythms of the economy. Cobham isn't one of them. Like others in the sector, it is a defensive play, which is a great attribute but means that the growth of the shares could be pedestrian as the recovery takes hold.

The second concern stems from the likelihood of cuts in defence spending, both here and in the US, as governments battle to contain yawning deficits and stave off the threat of credit ratings downgrades. That said, Cobham still offers exposure to some high growth areas such as intelligence, surveillance and cyber-security. Morgan Stanley says this should allow it to grow earnings at a compounded annual rate of 10 per cent over the three years to 2012. If achieved, that would put it well ahead of its peers.

It is also worth noting that the auguries are promising; investors need only look to the recent full-year results, which evidenced healthy rises in profits and revenues. So investors are faced with a dilemma, with the risk of some near-term pressure as traders switch out of defensives, coupled with the prospect of budget cuts, balanced against an evidently strong company with the potential for what could be strong growth.

It all comes down to valuation, which leaves little room for doubt. Cobham trades on a surprisingly thin multiple of 11.6 times Evolution's forecasts for 2010. That falls to 10.8 times on the numbers for 2011, suggesting that the market may be pricing in too much disappointment while at the same time overlooking the potential for growth. We said buy in November last year and, given the stock's attractive valuation, we say keep buying.



Immunodiagnostic Systs

Our view: Buy on weakness

Share price: 730p (-15p)

Immunodiagnostic Systems might sound vaguely like some flaky biotechnology stock but it is actually a solid company that makes diagnostic testing kits for the clinical and research markets. And yesterday's trading update had much to like about it, not least the fact that it beat Panmure's forecast revenues (£37.1m against £35.1m). Said revenues are 49 per cent up on the previous year and ahead in all of the company's diverse markets. Profits will be solidly in line with expectations too.

So, then, why the fall in the share price? Well, the problem is getting approval from the US Food and Drug Administration (USFDA) for the automated immuno-analyser IDS-iSYS. The company notes that approval times are lengthening, but it is still worrying and arguably grounds for caution about the stock, which would move into sharp reverse if the delay turned into something more worrying. It is also true that the shares have had a good run in recent months.

Panmure has Immunodiagnostic Systems on 16.9 times 2011 full-year earnings, which looks pricey, but is much more reasonable when compared to the company's peer group. The issue with the USFDA remains a worry for investors but the company generally looks in good shape and, if the shares fall further over the coming days, investors willing to take a risk should be prepared to take advantage. Buy on weakness.



Eckoh

Our view: Hold for now

Share price: 4.75p (Unchanged)

Eckoh provides what it calls "hosted speech recognition services" – those robot voices on the end of a telephone booking line. The next time you are negotiating with a machine to buy Vue cinema tickets, you will be talking to Eckoh. The company has changed hugely since it was founded in 1993 and is backing its "Speech Solution" operation to provide its main growth.

It may be a small operation but the client list includes some big names including National Rail Enquiries, the bookmaker William Hill, Parcelforce Worldwide and mobile phone operator O2. It also provided the automated phone-in lines for Comic Relief.

At the interim results in December, Eckoh reported that turnover in speech had risen 15 per cent year on year. Yet, the revenues declined overall because of a slide in the larger side of the business, the so-called Client IVR, or premium-rate phone services. Revenues in that division fell 28 per cent after it lost ITV as a client in December 2008, and IVR calls have further reduced as publishing clients have gone out of business. The future doesn't look great for the division, and management admit the market has been on a downward slope for a couple of years. Eckoh's speech business looks good but IVR issues worry us. Still, the shares are cheap, so hold for now.

Suggested Topics
News
people'It can last and it's terrifying'
Sport
Danny Welbeck's Manchester United future is in doubt
footballGunners confirm signing from Manchester United
Sport
footballStriker has moved on loan for the remainder of the season
News
people Emma Watson addresses celebrity nude photo leak
PROMOTED VIDEO
Sport
footballFeaturing Bart Simpson
News
Katie Hopkins appearing on 'This Morning' after she purposefully put on 4 stone.
peopleKatie Hopkins breaks down in tears over weight gain challenge
Arts and Entertainment
Olivia Colman topped the list of the 30 most influential females in broadcasting
tv
News
Kelly Brook
peopleA spokesperson said the support group was 'extremely disappointed'
Life and Style
techIf those brochure kitchens look a little too perfect to be true, well, that’s probably because they are
Sport
Andy Murray celebrates a shot while playing Jo-Wilfried Tsonga
TennisWin sets up blockbuster US Open quarter-final against Djokovic
News
ebooksAn unforgettable anthology of contemporary reportage
Arts and Entertainment
Hare’s a riddle: Kit Williams with the treasure linked to Masquerade
booksRiddling trilogy could net you $3m
Arts and Entertainment
Alex Kapranos of Franz Ferdinand performs live
music Pro-independence show to take place four days before vote
News
news Video - hailed as 'most original' since Benedict Cumberbatch's
News
i100
Life and Style
The longer David Sedaris had his Fitbit, the further afield his walks took him through the West Sussex countryside
lifeDavid Sedaris: What I learnt from my fitness tracker about the world
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Planning Manager (Training, Learning and Development) - London

£35000 - £38000 per annum + benefits: Ashdown Group: A highly successful, glob...

Business Anaylst

£60000 - £75000 per annum + BONUS + BENEFITS: Harrington Starr: Business Anal...

SQL Implementation Consultant (VB,C#, SQL, Java, Eclipse, integ

£40000 - £50000 per annum + benefits+bonus+package: Harrington Starr: SQL Impl...

Head of IT (Windows, Server, VMware, SAN, Fidessa, Equities)

£85000 per annum: Harrington Starr: Head of IT (Windows, Server, VMware, SAN, ...

Day In a Page

'I’ll tell you what I would not serve - lamb and potatoes': US ambassador hits out at stodgy British food served at diplomatic dinners

'I’ll tell you what I would not serve - lamb and potatoes'

US ambassador hits out at stodgy British food
Radio Times female powerlist: A 'revolution' in TV gender roles

A 'revolution' in TV gender roles

Inside the Radio Times female powerlist
Endgame: James Frey's literary treasure hunt

James Frey's literary treasure hunt

Riddling trilogy could net you $3m
Fitbit: Because the tingle feels so good

Fitbit: Because the tingle feels so good

What David Sedaris learnt about the world from his fitness tracker
Saudis risk new Muslim division with proposal to move Mohamed’s tomb

Saudis risk new Muslim division with proposal to move Mohamed’s tomb

Second-holiest site in Islam attracts millions of pilgrims each year
Alexander Fury: The designer names to look for at fashion week this season

The big names to look for this fashion week

This week, designers begin to show their spring 2015 collections in New York
Will Self: 'I like Orwell's writing as much as the next talented mediocrity'

'I like Orwell's writing as much as the next talented mediocrity'

Will Self takes aim at Orwell's rules for writing plain English
Meet Afghanistan's middle-class paint-ballers

Meet Afghanistan's middle-class paint-ballers

Toy guns proving a popular diversion in a country flooded with the real thing
Al Pacino wows Venice

Al Pacino wows Venice

Ham among the brilliance as actor premieres two films at festival
Neil Lawson Baker interview: ‘I’ve gained so much from art. It’s only right to give something back’.

Neil Lawson Baker interview

‘I’ve gained so much from art. It’s only right to give something back’.
The other Mugabe who is lining up for the Zimbabwean presidency

The other Mugabe who is lining up for the Zimbabwean presidency

Wife of President Robert Mugabe appears to have her sights set on succeeding her husband
The model of a gadget launch: Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed

The model for a gadget launch

Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed
Alice Roberts: She's done pretty well, for a boffin without a beard

She's done pretty well, for a boffin without a beard

Alice Roberts talks about her new book on evolution - and why her early TV work drew flak from (mostly male) colleagues
Get well soon, Joan Rivers - an inspiration, whether she likes it or not

Get well soon, Joan Rivers

She is awful. But she's also wonderful, not in spite of but because of the fact she's forever saying appalling things, argues Ellen E Jones
Doctor Who Into the Dalek review: A classic sci-fi adventure with all the spectacle of a blockbuster

A fresh take on an old foe

Doctor Who Into the Dalek more than compensated for last week's nonsensical offering